海思科：子公司HSK50042片剂和HSK55879片剂获受理

Core Viewpoint - The company announced that its subsidiary, Shanghai Haisco Shenno Pharmaceutical Technology Co., Ltd., has received a "Notice of Acceptance" from the National Medical Products Administration for two new drug applications [1] Group 1: Drug Development - HSK50042 is an oral, potent, and highly selective small molecule inhibitor intended for the treatment of respiratory diseases [1] - HSK55879 is an oral small molecule agonist aimed at treating metabolic system diseases [1] - Both drugs are classified as Category 1 chemical drugs [1]